论文部分内容阅读
目的评价国产阿卡波糖(卡博平)治疗2型糖尿病的临床疗效和安全性及治疗成本比。方法入选社区门诊中46例2型糖尿病患者,随机分为治疗组23例和对照组23例进行治疗和比较。治疗组加用国产阿卡波糖(卡博平)50~100mg,每日3次;对照组加用进口阿卡波糖(拜唐苹),剂量和服法同治疗组。治疗前2~4周平衡期,疗程为12周。结果与用药前相比,餐后血糖(PBG)均明显下降,空腹血糖(FBG)、糖化血红蛋白(Hb AIc)亦有所下降。治疗前后比较差异具有统计学意义(P<0.05)。两组间差异无统计学意义(P>0.05)。两组均未见明显不良反应。结论卡博平与拜唐苹在治疗2型糖尿病中的临床疗效、安全性及耐受性接近,但卡博平比拜唐苹的成本比更高。
Objective To evaluate the clinical efficacy, safety and cost-effectiveness of domestic acarbose (carbopol) in the treatment of type 2 diabetes mellitus. METHODS: Forty-six patients with type 2 diabetes mellitus were enrolled in the outpatient community and were randomly divided into treatment group (n = 23) and control group (n = 23) for treatment and comparison. The treatment group plus domestic acarbose (carbopine) 50 ~ 100mg, 3 times a day; the control group plus imported acarbose (Bai Tang Ping), dose and service method with the treatment group. 2 to 4 weeks before treatment, the balance period of 12 weeks. Results Compared with before treatment, postprandial blood glucose (PBG) were significantly decreased, fasting blood glucose (FBG), glycosylated hemoglobin (Hb AIc) also declined. The difference between before and after treatment was statistically significant (P <0.05). There was no significant difference between the two groups (P> 0.05). No obvious adverse reactions were found in both groups. Conclusion The efficacy, safety and tolerability of captopril and bei Tang Ping in the treatment of type 2 diabetes are similar, but the costs of carbopol and bebipan are higher.